Amol Padgaonkar

Amol Padgaonkar is a Director in our Intelligence & Insight business with over seven years of experience strategically supporting clients across the life sciences industry. In particular, Amol is deeply familiar with the oncology, hematology and inflammatory disease therapeutic areas; with expertise across various forms of engagements, Amol’s primary strategic focus includes early asset, asset life cycle and portfolio/therapeutic area planning. He enjoys serving as a critical thought partner for clients, leveraging his disease area content expertise and strategic insights to drive actionable and innovative solutions. Prior to joining Prescient, Amol received his PhD in molecular biology and cancer genetics from the Temple University School of Medicine in Philadelphia and completed his postdoctoral research at Mount Sinai School of Medicine in New York, where his thesis focused on the discovery and development of novel oncogenic kinase targets and inhibitors in triple-negative breast cancer.